Senior Vice-President Alexion Pharmaceuticals
In February 2014, Julie O'Neill was appointed senior vice-president of global operations and general manager in Ireland at Alexion Pharma.
Julie O’Neill is also be responsible for global manufacturing operations, including Alexion’s manufacturing plant in Smithfield, Rhode Island in the US as well as Alexion’s global supply chain operations.
Alexion is a global biopharmaceutical company focused on the development and delivery of therapies for severe and life-threatening rare disorders.
The Trinity College and UCD alumna began her career by opening four pharmacies in Dublin, and is now a leader in the Irish pharmaceutical industry. As former VP operations and general manager at Gilead Ireland, O'Neill established the California-based company's Irish subsidiary and a direct distribution hub for Gilead's EU-based subsidiaries and negotiated the acquisition of Nycomed in 2007. She also assumed the role of president at employers' group IBEC from 2011 to 2012.
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.
Alexion’s first commercial product is Soliris® (eculizumab), the world's first and only approved terminal complement inhibitor. Today, Soliris is approved in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in nearly 40 countries as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.